Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations at PAINWeek 2019 National Conference
September 04 2019 - 8:00AM
Centrexion Therapeutics Corporation, a company focused on
developing non-opioid, non-addictive therapies for the treatment of
chronic pain, today announced it will present one oral presentation
on CNTX-6970 and four poster presentations on CNTX-4975, CNTX-6970
and CNTX-6016 at the 13th Annual PAINWeek National Conference
taking place in Las Vegas, Nevada from September 3-7, 2019.
Full abstracts are available online at the PAINWeek Abstract
Book. The poster presentation details are as follows:
Oral Presentation
Title: Phase 1 Study of the Safety,
Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses
of the Selective Oral CCR2 Antagonist CNTX-6970 in Healthy
SubjectsSession Title: Poster/Podium
PresentationsPoster Number:
102Presentation Date & Time: Friday, September
6 at 11:20am PTLocation: POS-02
Poster Presentations
Title: Evaluation of the Efficacy of
Intra-articular CNTX-4975 in Subjects With Knee Osteoarthritis:
Results From an 8-Week StudySession Title:
Scientific Poster Session and ReceptionPoster
Number: 100Presentation Date & Time:
Thursday, September 5 from 6:30pm - 8:30pm
PTLocation: POS-01
Title: Phase 1 Study of the Safety,
Tolerability, and Pharmacokinetics of Single Ascending Doses of the
Novel Oral CCR2 Antagonist, CNTX-6970, in Healthy
VolunteersSession Title: Scientific Poster Session
and ReceptionPoster Number:
101Presentation Date & Time: Thursday,
September 5 from 6:30pm - 8:30pm PTLocation:
POS-01
Title: Evaluation of the Selective Oral CCR2
Antagonist CNTX-6970 in the Treatment of Osteoarthritis Pain;
Results from Preclinical Studies of Pharmacokinetics and
EfficacySession Title: Scientific Poster Session
and ReceptionPoster Number:
104Presentation Date & Time: Thursday,
September 5 from 6:30pm - 8:30pm PTLocation:
POS-01
Title: Evaluation of the Selective Oral CB2
Agonist CNTX-6016 for the Treatment of Neuropathic Pain:
Pharmacokinetic, Efficacy, and Safety Findings from Preclinical
StudiesSession Title: Scientific Poster Session
and ReceptionPoster Number:
103Presentation Date & Time: Thursday,
September 5 from 6:30pm - 8:30pm PTLocation:
POS-01
About OsteoarthritisOsteoarthritis (OA) is the
most common joint disease in the U.S., currently affecting more
than 30 million Americans, according to the U.S. Centers for
Disease Control. OA occurs when cartilage, the tissue that envelops
the structural bones within a joint, gradually deteriorates. These
changes cause pain, swelling and problems moving the joint.
Although OA can affect any joint, it most often affects joints in
the knees, hips, lower back and neck, small joints of the fingers
and the bases of the thumb and big toe. Over time, patients with
knee OA tend to become inactive due to pain and joint stiffness and
reduced function.
About CNTX-4975CNTX-4975, Centrexion’s most
advanced product candidate, is an investigational synthetic,
ultra-pure intra-articular injection of trans-capsaicin for the
treatment of moderate-to-severe pain associated with knee OA.
CNTX-4975 is designed to be administered directly into the joint
where the pain stimulus originates and to selectively and locally
target and disrupt the signaling of pain-sensing nerve fibers. In
January 2018, CNTX-4975 was granted Fast Track Designation by the
U.S. Food and Drug Administration for the treatment of
moderate-to-severe pain associated with knee OA.
About CNTX-6970CNTX-6970 is a novel, potent and
selective investigational CCR2 (C-C chemokine receptor type 2)
antagonist currently in Phase 1 clinical trials. Chemokine receptor
type 2, or CCR2, is the receptor for a cytokine known as monocyte
chemoattractant protein-1, or MCP-1. Pre-clinical data suggest that
CCR2, and MCP-1, are upregulated in immune cells, such as
macrophages, microglial cells and astrocytes which play a central
role in the origination of pain signals. CNTX-6970 has been shown
to reduce pain signaling by inhibiting the CCR2 receptor which has
a dual effect: stopping immune cells from releasing the potent
cytokine MCP-1 and stopping MCP-1 from stimulating pain fibers to
send pain signals. CNTX-6970 conferred analgesia in multiple
pre-clinical chronic pain models, with particular activity in
models of inflammatory pain. CNTX- 6970 is predicted to be well
suited to treat inflammatory chronic pain, and Phase 1 studies have
shown the treatment was well tolerated with demonstrated
pharmacologic and pharmacodynamic activity.
About CNTX-6016CNTX-6016 is a novel, potent and
highly selective investigational cannabinoid 2 (CB2) agonist
currently in Phase 1 clinical trials. There are two distinct
cannabinoid receptors, CB1 and CB2. A major factor holding back the
development of drugs targeting the cannabinoid receptors relates to
psychotropic adverse effects from CB1 activation in the central
nervous system, or CNS. Whereas adverse CNS effects appear to
relate to activation of CB1, published studies support that
activation of CB2 receptors results in analgesia without the CB1
psychotropic effects. In pre-clinical studies CNTX-6016 was shown
to be 16,000-fold selective for CB2 over CB1 and conferred
analgesia in multiple pre-clinical chronic pain models, with
particular activity in models of neuropathic pain. CNTX-6016 is
predicted to be well suited for the treatment of chronic
neuropathic pain, such as diabetic and autoimmune neuropathic pain
and chemotherapy induced neuropathy.
About Centrexion Therapeutics
CorporationCentrexion is a late clinical-stage
biopharmaceutical company focused on becoming the leader in
identifying, developing and commercializing novel, non-opioid and
non-addictive therapies to address the large unmet medical need for
the treatment of chronic pain.
Media ContactJulie Normart, W2O pure+1 (415)
946-1087Jnormart@purecommunications.com
Investor ContactCourtney Dugan, W2O pure+1
(212) 257-6723cdugan@w2ogroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Oct 2023 to Oct 2024